Relief Therapeutics Holding AG

Relief Therapeutics Holding AG is a Swiss-based commercial-stage biopharmaceutical company specializing in the development and commercialization of novel therapies for serious diseases with high unmet medical needs. Founded in 2013 and headquartered in Geneva, the company focuses on creating patent-protected pharmaceutical products, with an emphasis on specialty, rare, and ultra-rare conditions, particularly within dermatological and metabolic diseases. Its development strategy incorporates both innovative drug delivery systems and drug repurposing to enhance treatment efficacy, safety, and patient convenience for chronic and debilitating ailments. The company's diversified portfolio combines promising clinical-stage drug candidates with revenue-generating, out-licensed products. Notably, Relief Therapeutics has advanced programs targeting rare skin disorders and metabolic conditions, such as epidermolysis bullosa and phenylketonuria, alongside the development of RLF-100 (aviptadil)—a synthetic peptide investigated for respiratory and lung diseases, including pulmonary sarcoidosis. Through strategic acquisitions and partnerships, Relief Therapeutics continues to expand its footprint in biotechnology and medical research, leveraging a highly experienced management team and board with deep expertise in pharmaceutical innovation and capital markets.